Latest & greatest articles for preeclampsia

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on preeclampsia or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on preeclampsia and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for preeclampsia

81. Efficacy of calcium and vitamin D supplementation on the prevention of preeclampsia and maternal and neonatal outcomes in pregnancy: a systematic review and network meta-analysis

Efficacy of calcium and vitamin D supplementation on the prevention of preeclampsia and maternal and neonatal outcomes in pregnancy: a systematic review and network meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2016 PROSPERO

82. Which agent most effectively prevents preeclampsia? A systematic review with multi-treatment comparison (network meta-analysis) of large multicenter randomized controlled trials

Which agent most effectively prevents preeclampsia? A systematic review with multi-treatment comparison (network meta-analysis) of large multicenter randomized controlled trials Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email

2016 PROSPERO

83. Risk of chronic kidney disease after preeclampsia, HELLP and other hypertensive disorders of pregnancy: a systematic review of observational studies

Risk of chronic kidney disease after preeclampsia, HELLP and other hypertensive disorders of pregnancy: a systematic review of observational studies Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith

2016 PROSPERO

84. Risk of cardiovascular disease after preeclampsia, HELLP and other hypertensive disorders of pregnancy: a systematic review and meta-analysis

Risk of cardiovascular disease after preeclampsia, HELLP and other hypertensive disorders of pregnancy: a systematic review and meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne

2016 PROSPERO

85. Diagnostic value of sFlti/PIFG in preeclampsia: a systemic review and meta analysis

Diagnostic value of sFlti/PIFG in preeclampsia: a systemic review and meta analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2016 PROSPERO

87. Association Between Preeclampsia and Congenital Heart Defects. Full Text available with Trip Pro

Association Between Preeclampsia and Congenital Heart Defects. The risk of congenital heart defects in infants of women who had preeclampsia during pregnancy is poorly understood, despite shared angiogenic pathways in both conditions.To determine the prevalence of congenital heart defects in offspring of women with preeclampsia.Population-level analysis of live births before discharge, 1989-2012, was conducted for the entire province of Quebec, comprising a quarter of Canada's population. All (...) women who delivered an infant with or without heart defects in any Quebec hospital were included (N = 1,942,072 neonates).Preeclampsia or eclampsia with onset before or after 34 weeks of gestation.Presence of any critical or noncritical congenital heart defect detected in infants at birth, comparing prevalence in those exposed and not exposed to preeclampsia.The absolute prevalence of congenital heart defects was higher for infants of women with preeclampsia than those without it. Infants of women

2015 JAMA

88. Folic acid supplementation for the prevention of preeclampsia

Folic acid supplementation for the prevention of preeclampsia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing and effect measures Timing

2015 PROSPERO

89. Predictive value of miR-210 as a novel biomarker for predicting preeclampsia: a systematic review protocol

Predictive value of miR-210 as a novel biomarker for predicting preeclampsia: a systematic review protocol Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation

2015 PROSPERO

90. Systematic review on interpregnancy interval and risk of recurrent preeclampsia

Systematic review on interpregnancy interval and risk of recurrent preeclampsia Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2015 PROSPERO

91. Risk of preeclampsia and small for gestational age according to antioxidants levels throughout pregnancy

Risk of preeclampsia and small for gestational age according to antioxidants levels throughout pregnancy Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web

2015 PROSPERO

92. Systematic review with meta-analysis: Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia

Systematic review with meta-analysis: Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia | Evidence-Based Nursing We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our . Log in using your username (...) and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? Search for this keyword Search for this keyword Main menu Log in using your username and password For personal accounts OR managers of institutional accounts Username * Password * your user name or password? You are here Low-dose aspirin reduces morbidity and mortality in pregnant women at high-risk for preeclampsia Article Text Midwifery Systematic review with meta-analysis Low-dose

2015 Evidence-Based Nursing

93. Systematic review: Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia Full Text available with Trip Pro

Systematic review: Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia | BMJ Evidence-Based Medicine We use cookies to improve our service and to tailor our content and advertising to you. You can manage your cookie settings via your browser at any time. To learn more (...) period of aspirin use for prevention of preeclampsia Article Text Therapeutics/Prevention Systematic review Updated review identifies no adverse impact on mother or offspring during the perinatal period of aspirin use for prevention of preeclampsia Free Paul Leeson Statistics from Altmetric.com Commentary on : Henderson JT , Whitlock EP , O'Connor E , et al . Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the US Preventive Services Task

2015 Evidence-Based Medicine

94. Gestational Hypertension and Preeclampsia in Living Kidney Donors. Full Text available with Trip Pro

Gestational Hypertension and Preeclampsia in Living Kidney Donors. Young women wishing to become living kidney donors frequently ask whether nephrectomy will affect their future pregnancies.We conducted a retrospective cohort study of living kidney donors involving 85 women (131 pregnancies after cohort entry) who were matched in a 1:6 ratio with 510 healthy nondonors from the general population (788 pregnancies after cohort entry). Kidney donations occurred between 1992 and 2009 in Ontario (...) , Canada, with follow-up through linked health care databases until March 2013. Donors and nondonors were matched with respect to age, year of cohort entry, residency (urban or rural), income, number of pregnancies before cohort entry, and the time to the first pregnancy after cohort entry. The primary outcome was a hospital diagnosis of gestational hypertension or preeclampsia. Secondary outcomes were each component of the primary outcome examined separately and other maternal and fetal

2014 NEJM

95. Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: U.S. Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: U.S. Preventive Services Task Force Recommendation Statement. Update of the 1996 U.S. Preventive Services Task Force (USPSTF) recommendation on aspirin prophylaxis in pregnancy.The USPSTF reviewed the evidence on the effectiveness of low-dose aspirin in preventing preeclampsia in women at increased risk and in decreasing adverse maternal and perinatal health outcomes, and assessed the maternal and fetal harms (...) of low-dose aspirin during pregnancy.This recommendation applies to asymptomatic pregnant women who are at increased risk for preeclampsia and who have no prior adverse effects with or contraindications to low-dose aspirin.The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia. (B recommendation).

2014 Annals of Internal Medicine

96. Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. (Abstract)

Low-dose aspirin for prevention of morbidity and mortality from preeclampsia: a systematic evidence review for the U.S. Preventive Services Task Force. Preeclampsia is a leading cause of maternal and perinatal morbidity and mortality.To systematically review benefits and harms of low-dose aspirin for preventing morbidity and mortality from preeclampsia.MEDLINE, Database of Abstracts of Reviews of Effects, PubMed, and Cochrane Central Register of Controlled Trials (January 2006 to June 2013 (...) ); previous systematic reviews, clinical trial registries, and surveillance searches for large studies (June 2013 to February 2014).Randomized, controlled trials (RCTs) to assess benefits among women at high preeclampsia risk and RCTs or large cohort studies of harms among women at any risk level. English-language studies of fair or good quality were included.Dual quality assessment and abstraction of studies.Two large, multisite RCTs and 13 smaller RCTs of high-risk women (8 good-quality) were included

2014 Annals of Internal Medicine

97. Presence of Periodontal Disease in Pregnant Women Increases the Risk of Developing Preeclampsia

Presence of Periodontal Disease in Pregnant Women Increases the Risk of Developing Preeclampsia UTCAT2704, Found CAT view, CRITICALLY APPRAISED TOPICs University: | | ORAL HEALTH EVIDENCE-BASED PRACTICE PROGRAM View the CAT / Title Presence of Periodontal Disease in Pregnant Women Increases the Risk of Developing Preeclampsia Clinical Question Is periodontitis a risk factor for development of preeclampsia during pregnancy? Clinical Bottom Line Research has shown that periodontal disease (...) contributes to the development of preeclampsia during pregnancy. Best Evidence (you may view more info by clicking on the PubMed ID link) PubMed ID Author / Year Patient Group Study type (level of evidence) #1) Sgolastra/2013 384 studies Meta-Analysis Key results This meta-analysis concluded that a relationship between pregnant women with periodontal disease (PD) and development of preeclampsia (PE) does indeed exist. Originally, 384 studies were reviewed; however, only 15 studies qualified for inclusion

2014 UTHSCSA Dental School CAT Library

98. Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication

Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication Final Update Summary: Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive Medication - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 11/16/2018 6:27:19 PM You are here: Final Summary Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia: Preventive (...) Medication Release Date: September 2014 Recommendation Summary Low-Dose Aspirin Use for the Prevention of Morbidity and Mortality From Preeclampsia Population Recommendation Grade Pregnant Women Who Are At High Risk for Preeclampsia The USPSTF recommends the use of low-dose aspirin (81 mg/d) as preventive medication after 12 weeks of gestation in women who are at high risk for preeclampsia. ( ) Related Information for Consumers Related Information for Health Professionals There is no related information

2014 U.S. Preventive Services Task Force

99. Non-0 blood groups are independent risk factor for preeclampsia: a meta-analysis

Non-0 blood groups are independent risk factor for preeclampsia: a meta-analysis Print | PDF PROSPERO This information has been provided by the named contact for this review. CRD has accepted this information in good faith and registered the review in PROSPERO. CRD bears no responsibility or liability for the content of this registration record, any associated files or external websites. Email salutation (e.g. "Dr Smith" or "Joanne") for correspondence: Organisation web address: Timing

2014 PROSPERO

100. Risk assessment for preeclampsia in nulliparous women at 11-13 weeks gestational age: prospective evaluation of two algorithms (Abstract)

Risk assessment for preeclampsia in nulliparous women at 11-13 weeks gestational age: prospective evaluation of two algorithms To evaluate two algorithms for prediction of preeclampsia in a population of nulliparous women in Norway.Prospective screening study.National Centre for Fetal Medicine in Trondheim, Norway.Five hundred and forty-one nulliparous women.The women were examined between 11(+0) and 13(+6) weeks with interviews for maternal characteristics and measurements of mean arterial (...) pressure, uterine artery pulsatility index, pregnancy-associated plasma protein A and placental growth factor. The First Trimester Screening Program version 2.8 by The Fetal Medicine Foundation (FMF) was compared with the Preeclampsia Predictor TM version 1 revision 2 by Perkin Elmer (PREDICTOR).Prediction of preeclampsia requiring delivery before 37 weeks, before 42 weeks and late preeclampsia (delivery after 34 weeks).The performance of the two algorithms was similar, but quite poor, for prediction

2014 EvidenceUpdates